On Friday, January 12, 2024, the financial world was shaken by a coordinated announcement from the U.S. Attorney's Office and the SEC detailing a massive fraud scheme at the heart of Morgan Stanley's block trading business. The case centered on a profound breach of trust orchestrated by the firm and its former Head of U.S. Equity Syndicate Desk, Pawan Passi. The resolution that day—a Non-Prosecution Agreement (NPA) for the firm and a Deferred Prosecution Agreement (DPA) for the executive—set in motion one of the most significant enforcement actions of the decade. Now, nearly two years later, we can confirm the financial score is settled and the professional consequences are in full effect. 1. The Core Deception: The Secret Tipped The fraud occurred from 2018 through August 2021. The scheme was simple but effective: The Broken Promise: Morgan Stanley, through Passi, promised block sellers (clients needing to sell large quantities of stock) that their intentions would...
The recent $37.76 Million Settlement with CVS for over-dispensing insulin pens is more than just a large fine; it’s a powerful illustration of the government’s primary weapon against healthcare fraud: The False Claims Act (FCA). This case provides a crucial look into the high-stakes legal framework that protects taxpayer-funded programs like Medicare, Medicaid, and TRICARE. What Law Was Broken? The False Claims Act (FCA) The core of the CVS settlement is a violation of the Federal False Claims Act (31 U.S.C. §§ 3729-3733). This is the government’s most effective tool for recovering funds lost due to fraud. 1. The Core Violation: A "False Claim" The FCA targets anyone who knowingly submits, or causes to be submitted, a false or fraudulent claim for payment to the U.S. government. This law targets anyone who knowingly submits, or causes to be submitted, a false or fraudulent claim for payment to the U.S. government. In the CVS case, the false claims were rooted in t...